Email updates

Keep up to date with the latest news and content from Diagnostic Pathology and BioMed Central.

Open Access Research

High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma

Wan-Ting Huang1 and Shih-Sung Chuang2*

Author affiliations

1 Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

2 Department of Pathology, Chi-Mei Medical Center, Tainan, Taipei Medical University and National Taiwan University Hospital, Taipei, Taiwan

For all author emails, please log on.

Citation and License

Diagnostic Pathology 2013, 8:16  doi:10.1186/1746-1596-8-16

Published: 4 February 2013

Abstract

Background

MET is a proto-oncogene with its copy number (CN) alterations been reported in some cancers, but not in primary intestinal diffuse large B-cell lymphoma (PI-DLBL) yet.

Methods

In this retrospective study, we performed histology and chart reviews, immunohistochemistry and quantitative polymerase chain reaction for MET CN alterations on 28 surgically resected PI-DLBLs.

Results

There were 12 men and 16 women with a median age of 70 and a mean follow-up of 32 months. The median MET CN was 2.20 (range, 1.04 to 3.35). CN gain was observed in 11 cases, including 5 with CN greater than 3. Nine patients (32%) had diploid CN and eight (29%) with CN loss. Patients with gain or diploid CN showed significantly worse prognosis (P = 0.046) than those with CN loss. Furthermore, MET CN greater than 3 was associated with an adverse outcome (P = 0.003). Intestinal perforation at presentation was the sole clinicopathological factor associated with a poor prognosis (P = 0.004) and perforation was correlated with CN greater than 3 (P = 0.002).

Conclusions

Our finding of MET CN gain as a poor prognostic factor in PI-DLBL patients might serve as the rationale for targeting MET signaling pathway in the treatment of these patients.

Keywords:
Copy number; Diffuse large B-cell lymphoma; Intestine; MET; Primary intestinal diffuse large B-cell lymphoma; Taiwan